Protocol for isolating patient-derived ascites cells and extracellular vesicles from gastric cancer peritoneal metastases.
Peritoneal carcinomatosis (PC) cells and extracellular vesicles (EVs) from gastric cancer ascites are valuable for studying tumor-stroma interactions.
APA
Fan Y, Vykoukal JV, et al. (2025). Protocol for isolating patient-derived ascites cells and extracellular vesicles from gastric cancer peritoneal metastases.. STAR protocols, 6(4), 104133. https://doi.org/10.1016/j.xpro.2025.104133
MLA
Fan Y, et al.. "Protocol for isolating patient-derived ascites cells and extracellular vesicles from gastric cancer peritoneal metastases.." STAR protocols, vol. 6, no. 4, 2025, pp. 104133.
PMID
41105517
Abstract
Peritoneal carcinomatosis (PC) cells and extracellular vesicles (EVs) from gastric cancer ascites are valuable for studying tumor-stroma interactions. Here, we present a protocol for isolating PC cells and EVs from patient ascites. We describe steps for PC cell culture, iodixanol-based EV purification, electron microscopy, nanoparticle tracking analysis, flow cytometry, and proteomic profiling. This protocol also includes TD-139 loading into exosomes for functional assays to evaluate their role in modulating the tumor microenvironment. For complete details on the use and execution of this protocol, please refer to Fan et al..
MeSH Terms
Humans; Stomach Neoplasms; Extracellular Vesicles; Ascites; Peritoneal Neoplasms; Proteomics; Tumor Microenvironment; Flow Cytometry; Cell Line, Tumor; Cell Separation
같은 제1저자의 인용 많은 논문 (5)
- Single-Cell sequencing investigation of endoplasmic reticulum stress-related genes in gastric cancer prognostic models and identification of NOX5 as a novel therapeutic target.
- Synergistic CRISPR/Cas12a-Nanozyme System for Iontronic Sensing of Site-Specific Septin9 Methylation.
- Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma.
- Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses.
- First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.